IPP Bureau
Strides posts record Q3 EBITDA of Rs. 235.9 crore, operational PAT Up 39% YoY
By IPP Bureau - February 02, 2026
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Indoco Remedies bags USFDA nod for Lacosamide oral solution
By IPP Bureau - February 02, 2026
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
Dr Lal PathLabs reports Q3 revenue of Rs 660 crore, posts strong growth amid labour code impact
By IPP Bureau - February 02, 2026
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
Budget 2026-27: Government launches Rs. 10,000 crore Biopharma SHAKTI Scheme to build global manufacturing hub
By IPP Bureau - February 01, 2026
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
By IPP Bureau - February 01, 2026
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Budget 2026–27: Rs. 1,06,530.42 crore allocated to Ministry of Health and Family Welfare
By IPP Bureau - February 01, 2026
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
By IPP Bureau - January 31, 2026
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
AstraZeneca expands obesity and diabetes pipeline with $1.2B CSPC deal
By IPP Bureau - January 31, 2026
CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
Astec LifeSciences posts robust Q3 growth
By IPP Bureau - January 31, 2026
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
By IPP Bureau - January 31, 2026
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
Aster DM Healthcare reports solid Q3 FY26 growth, combined proforma revenue up 15%
By IPP Bureau - January 31, 2026
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Gland Pharma reports robust Q3 FY26 results: revenue up 22%, adj. PAT soars 37%
By IPP Bureau - January 30, 2026
The base Gland business posted ?11,790 million in revenue, up 16% YoY
Biocon Biologics gets credit boost from S&P, outlook stable
By IPP Bureau - January 30, 2026
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue
By IPP Bureau - January 30, 2026
The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules
